Blockmans, Daniel, Persoons, Philippe, Van Houdenhove, Boudewijn et al. · The American journal of medicine · 2006 · DOI
This study tested whether methylphenidate (a stimulant medication) could help reduce fatigue and improve concentration in ME/CFS patients. Sixty patients took either methylphenidate or placebo for 4 weeks each in alternating order. The medication did reduce fatigue and concentration problems compared to placebo, but only about 17–22% of patients showed clinically meaningful improvement.
This is one of the few randomized controlled trials testing a pharmacological intervention in ME/CFS, addressing the lack of evidence-based medical treatments. The findings suggest methylphenidate may benefit a subset of patients with significant cognitive symptoms, potentially opening avenues for future research into responder characteristics and optimal dosing strategies.
This study does not establish that methylphenidate is an effective treatment for ME/CFS broadly—only 17–22% of patients showed clinically meaningful benefit. The short 4-week duration means long-term safety and efficacy are unknown, and the study does not identify which patient characteristics predict response to treatment.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →